Dendritic cells pulsed with Hsp70 and HBxAg induce specific antitumor immune responses in hepatitis B virus‑associated hepatocellular carcinoma

Wang,Hui; Feng,Fang; Wang,Xiao‑Ping; Wang,Rou‑Shu; Wu,Ying; Zhu,Min‑Gao; Zhang,Hong; Zhuang,Zhi‑Xiang

doi:10.3892/mmr.2015.4654

Dendritic cells pulsed with Hsp70 and HBxAg induce specific antitumor immune responses in hepatitis B virus‑associated hepatocellular carcinoma

Authors:
- Hui Wang
- Fang Feng
- Xiao‑Ping Wang
- Rou‑Shu Wang
- Ying Wu
- Min‑Gao Zhu
- Hong Zhang
- Zhi‑Xiang Zhuang
View Affiliations

Affiliations: Department of Oncology, The Second Affiliated Hospital, Soochow University, Suzhou, Jiangsu 215004, P.R. China
Published online on: December 7, 2015 https://doi.org/10.3892/mmr.2015.4654
Pages: 1077-1082
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have drawn attention to dendritic cell (DC) vaccines; particularly the application of the tumor‑associated antigen‑targeted DC vaccine. The present study analyzed DCs derived from a normal individual and pulsed the cells with heat shock protein 70 peptide (Hsp70) and/or hepatitis B virus x antigen (HBxAg), a hepatocellular carcinoma (HCC)‑associated antigen. It was then investigated whether this method of vaccination induced strong therapeutic antitumor immunity. The results revealed that the Hsp70/HBxAg complex‑activated phenotype improves the functional maturation of DCs compared with using Hsp70 or HBxAg alone. Compared with either Hsp70 or HBxAg alone, matured DCs pulsed with the Hsp70/HBxAg complex stimulated a high level of autologous T‑cell proliferation and induced HCC‑specific cytotoxic T lymphocytes, which specifically killed HCC cells through a major histocompatibility complex class I mechanism. These results indicated that a vaccination therapy using DCs co‑pulsed with the Hsp70/HBxAg complex is an effective strategy for immunotherapy and may offer a useful approach to protect against HCC.

View Figures

View References

1	Arzumanyan A, Reis HM and Feitelson MA: Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 13:123–135. 2013. View Article : Google Scholar : PubMed/NCBI
2	Liu XH, Lin J, Zhang SH, Zhang SM, Feitelson MA, Gao HJ and Zhu MH: COOH-terminal deletion of HBx gene is a frequent event in HBV-associated hepatocellular carcinoma. World J Gastroenterol. 14:1346–1352. 2008. View Article : Google Scholar : PubMed/NCBI
3	Lehman EM and Wilson ML: Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: A systematic review and meta-analysis. Int J Cancer. 124:690–697. 2009. View Article : Google Scholar
4	Wang Z, Zhang G, Wu J and Jia M: Adjuvant therapy for hepatocellular carcinoma: Current situation and prospect. Drug Discov Ther. 7:137–143. 2013.PubMed/NCBI
5	Ibrahim SM, Lewandowski RJ, Sato KT, Gates VL, Kulik L, Mulcahy MF, Ryu RK, Omary RA and Salem R: Radioembolization for the treatment of unresectable hepatocellular carcinoma: A clinical review. World J Gastroenterol. 14:1664–1669. 2008. View Article : Google Scholar : PubMed/NCBI
6	Palucka K and Banchereau J: Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 12:265–277. 2012. View Article : Google Scholar : PubMed/NCBI
7	Zhan HL, Gao X, Pu XY, Li W, Li ZJ, Zhou XF and Qiu JG: A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma. Chin Med J (Engl). 125:3771–3777. 2012.
8	Berntsen A, Trepiakas R, Wenandy L, Geertsen PF, thor Straten P, Andersen MH, Pedersen AE, Claesson MH, Lorentzen T, Johansen JS and Svane IM: Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: A clinical phase 1/2 trial. J Immunother. 31:771–780. 2008. View Article : Google Scholar : PubMed/NCBI
9	Murphy ME: The HSP70 family and cancer. Carcinogenesis. 34:1181–1188. 2013. View Article : Google Scholar : PubMed/NCBI
10	Multhoff G, Pockley AG, Streffer C and Gaipl US: Dual role of heat shock proteins (HSPs) in anti-tumor immunity. Curr Mol Med. 12:1174–1182. 2012. View Article : Google Scholar : PubMed/NCBI
11	Ciocca DR, Cayado-Gutierrez N, Maccioni M and Cuello-Carrion FD: Heat shock proteins (HSPs) based anti-cancer vaccines. Curr Mol Med. 12:1183–1197. 2012. View Article : Google Scholar : PubMed/NCBI
12	Wang XH, Qin Y, Hu MH and Xie Y: Dendritic cells pulsed with hsp70-peptide complexes derived from human hepatocellular carcinoma induce specific anti-tumor immune responses. World J Gastroenterol. 11:5614–5620. 2005. View Article : Google Scholar : PubMed/NCBI
13	Li QL, Bu N, Yu YC, Hua W and Xin XY: Ex vivo experiments of human ovarian cancer ascites-derived exosomes presented by dendritic cells derived from umbilical cord blood for immunotherapy treatment. Clin Med Oncol. 2:461–467. 2008.
14	Yang JY, Cao DY, Xue Y, Yu ZC and Liu WC: Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells. Hum Immunol. 71:255–262. 2010. View Article : Google Scholar
15	Zhang Z, Du X, Zhao C, Cao B, Zhao Y and Mao X: The antidepressant amitriptyline shows potent therapeutic activity against multiple myeloma. Anticancer Drugs. 24:792–798. 2013. View Article : Google Scholar : PubMed/NCBI
16	Steinman RM: Dendritic cells and the control of immunity: Enhancing the efficiency of antigen presentation. Mt Sinai J Med. 68:160–166. 2001.PubMed/NCBI
17	Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature. 392:245–252. 1998. View Article : Google Scholar : PubMed/NCBI
18	Ovali E, Dikmen T, Sonmez M, Yilmaz M, Unal A, Dalbasti T, Kuzeyli K, Erturk M and Omay SB: Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine: A safety study. J Exp Clin Cancer Res. 26:209–214. 2007.PubMed/NCBI
19	Dannull J, Haley NR, Archer G, Nair S, Boczkowski D, Harper M, De Rosa N, Pickett N, Mosca PJ, Burchette J, et al: Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Invest. 123:3135–3145. 2013. View Article : Google Scholar : PubMed/NCBI
20	Abdul Hafid SR, Chakravarthi S, Nesaretnam K and Radhakrishnan AK: Tocotrienol-adjuvanted dendritic cells inhibit tumor growth and metastasis: A murine model of breast cancer. PLoS One. 8:e747532013. View Article : Google Scholar : PubMed/NCBI
21	Kandalaft LE, Powell DJ Jr, Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA, et al: Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology. 2:e226642013. View Article : Google Scholar : PubMed/NCBI
22	Gautam PK, Kumar S, Deepak P and Acharya A: Morphological effects of autologous hsp70 on peritoneal macrophages in a murine T cell lymphoma. Tumour Biol. 34:3407–3415. 2013. View Article : Google Scholar : PubMed/NCBI
23	Vrieling M, Santema W, Vordermeier M, Rutten V and Koets A: Hsp70 vaccination-induced primary immune responses in efferent lymph of the draining lymph node. Vaccine. 31:4720–4727. 2013. View Article : Google Scholar : PubMed/NCBI
24	Khanna R: Tumour surveillance: Missing peptides and MHC molecules. Immunol Cell Biol. 76:20–26. 1998. View Article : Google Scholar : PubMed/NCBI
25	Lu JW, Yang WY, Tsai SM, Lin YM, Chang PH, Chen JR, Wang HD, Wu JL, Jin SL, Yuh CH, et al: Liver-specific expressions of HBx and src in the p53 mutant trigger hepatocarcinogenesis in zebrafish. PLoS One. 8:e769512013. View Article : Google Scholar : PubMed/NCBI
26	Buchmann P, Dembek C, Kuklick L, Jäger C, Tedjokusumo R, von Freyend MJ, Drebber U, Janowicz Z, Melber K, Protzer U, et al: A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine. 31:1197–1203. 2013. View Article : Google Scholar : PubMed/NCBI
27	Shi M, Qian S, Chen WW, Zhang H, Zhang B, Tang ZR, Zhang Z and Wang FS: Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro. Clin Exp Immunol. 147:277–286. 2007. View Article : Google Scholar : PubMed/NCBI
28	Cassel JA, Ilyin S, McDonnell ME and Reitz AB: Novel inhibitors of heat shock protein Hsp70-mediated luciferase refolding that bind to DnaJ. Bioorg Med Chem. 20:3609–3614. 2012. View Article : Google Scholar : PubMed/NCBI
29	Bajana S, Herrera-González N, Narváez J, Torres-Aguilar H, Rivas-Carvalho A, Aguilar SR and Sánchez-Torres C: Differential CD4(+) T-cell memory responses induced by two subsets of human monocyte-derived dendritic cells. Immunology. 122:381–393. 2007. View Article : Google Scholar : PubMed/NCBI
30	Harty JT, Tvinnereim AR and White DW: CD8+ T cell effector mechanisms in resistance to infection. Annu Rev Immunol. 18:275–308. 2000. View Article : Google Scholar : PubMed/NCBI
31	Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD and Allen PM: Eradication of established tumors by CD8⁺ T cell adoptive immunotherapy. Immunity. 13:265–276. 2000. View Article : Google Scholar : PubMed/NCBI